|
1
|
Aarsland D, Andersen K, Larsen JP, Lolk A,
Nielsen H and Kragh-Sørensen P: Risk of dementia in Parkinson's
disease-A community-based, prospective study. Neurology.
56:730–736. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aarsland D, Zaccai J and Brayne C: A
systematic review of prevalence studies of dementia in Parkinson's
disease. Mov Disord. 20:1255–1263. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mueller C, Ballard C, Corbett A and
Aarsland D: The prognosis of dementia with Lewy bodies. Lancet
Neurol. 16:390–398. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lippa CF, Duda JE, Grossman M, Hurtig HI,
Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, et
al: DLB and PDD boundary issues: diagnosis, treatment, molecular
pathology, and biomarkers. Neurology. 68:812–819. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gomperts SN: Lewy body dementias: Dementia
with Lewy bodies and Parkinson disease dementia. Continuum
(Minneapolis Minn). 22:435–463. 2016.
|
|
6
|
Matsunaga S, Kishi T and Iwata N:
Memantine for Lewy body disorders: Systematic review and
meta-analysis. Am J Geriatr Psychiatry. 23:373–383. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsunaga S, Kishi T, Yasue I and Iwata N:
Cholinesterase inhibitors for Lewy body disorders: A meta-analysis.
Int J Neuropsychopharmacol. 19:pyv0862015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stinton C, McKeith I, Taylor JP, Lafortune
L, Mioshi E, Mak E, Cambridge V, Mason J, Thomas A and O'Brien JT:
Pharmacological management of Lewy body dementia: A systematic
review and meta-analysis. Am J Psychiatry. 172:731–742. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang HF, Yu JT, Tang SW, Jiang T, Tan CC,
Meng XF, Wang C, Tan MS and Tan L: Efficacy and safety of
cholinesterase inhibitors and memantine in cognitive impairment in
Parkinson's disease, Parkinson's disease dementia, and dementia
with Lewy bodies: Systematic review with meta-analysis and trial
sequential analysis. J Neurol Neurosurg Psychiatry. 86:135–143.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Z, Yu Z and Zhang J, Wang J, Sun C,
Wang P and Zhang J: Impact of rivastigmine on cognitive dysfunction
and falling in Parkinson's disease patients. Eur Neurol. 74:86–91.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gibb WR and Lees AJ: The relevance of the
lewy body to the pathogenesis of idiopathic Parkinson's disease. J
Neurol Neurosurg Psychiatry. 51:745–752. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hughes AJ, Daniel SE, Kilford L and Lees
AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's
disease: A clinico-pathological study of 100 cases. J Neurol
Neurosurg Psychiatry. 55:181–184. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Larsen JP, Dupont E and Tandberg E:
Clinical diagnosis of Parkinson's disease. Proposal of diagnostic
subgroups classified at different levels of confidence. Acta Neurol
Scand. 89:242–251. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Litvan I, Bhatia KP, Burn DJ, Goetz CG,
Lang AE, McKeith I, Quinn N, Sethi KD, Shults C and Wenning GK;
Movement Disorders Society Scientific Issues Committee, : Movement
disorders society scientific issues committee report: SIC task
force appraisal of clinical diagnostic criteria for Parkinsonian
disorders. Mov Disord. 18:467–486. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
American Psychiatric Association (APA):
Diagnostic and statistical manual of mental disorders. 4th.
American Psychiatric Association; Washington, DC: 1994
|
|
16
|
McKeith IG, Dickson DW, Lowe J, Emre M,
O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, et
al: Diagnosis and management of dementia with lewy bodies: Third
report of the DLB consortium. Neurology. 65:1863–1872. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Higgins JPT, Deeks JJ and Altman DG:
Chapter 16: Special topics in statistics. Higgins JPT and Green S:
Cochrane Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011). The Cochrane Collaboration. 2011,
http://www.cochrane-handbook.org
|
|
18
|
Higgins JPT, Altman DJ and Sterne JAC:
Chapter 8: Assessing risk of bias in included studies. Higgins JPT
and Green S: Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 (updated March 2011). The Cochrane
Collaboration. 2011, http://www.cochrane-handbook.org
|
|
19
|
Guyatt GH, Oxman AD, Vist GE, Kunz R,
Falck-Ytter Y, Alonso-Coello P and Schünemann HJ; GRADE, : Working
Group: GRADE: An emerging consensus on rating quality of evidence
and strength of recommendations. BMJ. 336:924–926. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mantel N and Haenszel W: Statistical
aspects of the analysis of data from retrospective studies of
disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
|
|
21
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ikeda M, Mori E, Matsuo K, Nakagawa M and
Kosaka K: Donepezil for dementia with Lewy bodies: A randomized,
placebo-controlled, confirmatory phase III trial. Alzheimers Res
Ther. 7:42015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mori E, Ikeda M and Kosaka K:
Donepezil-DLB Study Investigators: Donepezil for dementia with Lewy
bodies: A randomized, placebo-controlled trial. Ann Neurol.
72:41–52. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aarsland D, Laake K, Larsen JP and Janvin
C: Donepezil for cognitive impairment in Parkinson's disease: A
randomised controlled study. J Neurol Neurosurg Psychiatry.
72:708–712. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dubois B, Tolosa E, Katzenschlager R, Emre
M, Lees AJ, Schumann G, Pourcher E, Gray J, Thomas G, Swartz J, et
al: Donepezil in Parkinson's disease dementia: A randomized,
double-blind efficacy and safety study. Mov Disord. 27:1230–1238.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leroi I, Brandt J, Reich SG, Lyketsos CG,
Grill S, Thompson R and Marsh L: Randomized placebo-controlled
trial of donepezil in cognitive impairment in Parkinson's disease.
Int J Geriatr Psychiatry. 19:1–8. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ravina B, Putt M, Siderowf A, Farrar JT,
Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S
and Simuni T: Donepezil for dementia in Parkinson's disease: A
randomised, double blind, placebo controlled, crossover study. J
Neurol Neurosurg Psychiatry. 76:934–939. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
McKeith I, Del Ser T, Spano P, Emre M,
Wesnes K, Anand R, Cicin-Sain A, Ferrara R and Spiegel R: Efficacy
of rivastigmine in dementia with Lewy bodies: A randomised,
double-blind, placebo-controlled international study. Lancet.
356:2031–2036. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Emre M, Aarsland D, Albanese A, Byrne EJ,
Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A,
et al: Rivastigmine for dementia associated with Parkinson's
disease. N Engl J Med. 351:2509–2518. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mamikonyan E, Xie SX, Melvin E and
Weintraub D: Rivastigmine for mild cognitive impairment in
Parkinson disease: A placebo-controlled study. Mov Disord.
30:912–918. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wesnes KA, McKeith IG, Ferrara R, Emre M,
Del Ser T, Spano PF, Cicin-Sain A, Anand R and Spiegel R: Effects
of rivastigmine on cognitive function in dementia with lewy bodies:
A randomised placebo-controlled international study using the
cognitive drug research computerised assessment system. Dement
Geriatr Cogn Disord. 13:183–192. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Leroi I, Overshott R, Byrne EJ, Daniel E
and Burns A: Randomized controlled trial of memantine in dementia
associated with Parkinson's disease. Mov Disord. 24:1217–1221.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aarsland D, Ballard C, Walker Z, Bostrom
F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L and
Londos E: Memantine in patients with Parkinson's disease dementia
or dementia with Lewy bodies: A double-blind, placebo-controlled,
multicentre trial. Lancet Neurol. 8:613–618. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Emre M, Tsolaki M, Bonuccelli U, Destée A,
Tolosa E, Kutzelnigg A, Ceballos-Baumann A, Zdravkovic S, Bladström
A and Jones R; 11018 Study Investigators, : Memantine for patients
with Parkinson's disease dementia or dementia with Lewy bodies: A
randomised, double-blind, placebo-controlled trial. Lancet Neurol.
9:969–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stubendorff K, Larsson V, Ballard C,
Minthon L, Aarsland D and Londos E: Treatment effect of memantine
on survival in dementia with Lewy bodies and Parkinson's disease
with dementia: A prospective study. BMJ Open. 4:e0051582014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Manabe Y, Ino T, Yamanaka K and Kosaka K:
Increased dosage of donepezil for the management of behavioural and
psychological symptoms of dementia in dementia with Lewy bodies.
Psychogeriatrics. 16:202–208. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mori E, Ikeda M, Nakai K, Miyagishi H,
Nakagawa M and Kosaka K: Increased plasma donepezil concentration
improves cognitive function in patients with dementia with Lewy
bodies: An exploratory pharmacokinetic/pharmacodynamic analysis in
a phase 3 randomized controlled trial. J Neurol Sci. 366:184–190.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ukai K, Fujishiro H, Iritani S and Ozaki
N: Long-term efficacy of donepezil for relapse of visual
hallucinations in patients with dementia with Lewy bodies.
Psychogeriatrics. 15:133–137. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Litvinenko IV, Odinak MM, Mogil'naya VI
and Emelin AY: Efficacy and safety of galantamine (reminyl) for
dementia in patients with Parkinson's disease (an open controlled
trial). Neurosci Behav Physiol. 38:937–945. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Larsson V, Aarsland D, Ballard C, Minthon
L and Londos E: The effect of memantine on sleep behaviour in
dementia with Lewy bodies and Parkinson's disease dementia. Int J
Geriatr Psychiatry. 25:1030–1038. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Emre M, Poewe W, De Deyn PP, Barone P,
Kulisevsky J, Pourcher E, van Laar T, Storch A, Micheli F, Burn D,
et al: Long-term safety of rivastigmine in parkinson disease
dementia: An open-label, randomized study. Clin Neuropharmacol.
37:9–16. 2014.PubMed/NCBI
|
|
42
|
Sherman DS, Mauser J, Nuno M and Sherzai
D: The efficacy of cognitive intervention in mild cognitive
impairment (MCI): A meta-analysis of outcomes on neuropsychological
measures. Neuropsychol Rev. 27:440–484. 2017. View Article : Google Scholar : PubMed/NCBI
|
